Cancer related to Zantac (ranitidine)
Since coming to the market in 1983 as a prescription medication which later became available over the counter in 1996, the manufacturers of the antacid drug, Zantac (ranitidine), harbored a very big secret. It wasn’t until a voluntary recall of Zantac in October of 2019 and then an official recall requesting removal of all ranitidine products from the market by the FDA on April 1, 2020, that the secret was revealed.
So what was the secret that manufacturers knew, but did not disclose to the FDA and the people of the United States? It was that Zantac and all its generic forms had an unstable molecular make-up, which under normal conditions breaks down into high levels of a well-known cancer-causing agent, N-Nitrosodimethylamine (“NDMA”) putting hundreds of thousands of consumers at high risk for developing different forms of cancers.
The manufacturers of Zantac (ranitidine) marketed it for over thirty (30) years as being a safe and effective medication to treat heart burn-related pain which brought in sales of over $1 billion dollars to the pharmaceutical industry. But, all the while, they knew Zantac (ranitidine) was anything but safe and they chose to prioritize profits over people.